Keybanc analyst Paul Knight maintains Repligen (NASDAQ:RGEN) with a Overweight and raises the price target from $245 to $260.
Keybanc Maintains Overweight on Repligen, Raises Price Target to $260
Keybanc analyst Paul Knight maintains Repligen (NASDAQ:RGEN) with a Overweight and raises the price target from $245 to $260.
Related Posts
Mobiquity Technologies Reports Partnership With A-Nation To Provide Data, Programmatic Advertising, No Terms Disclosed
Mobiquity Technologies, Inc. (NASDAQ:MOBQ) (the “Company”), a leading provider of next-generation advertising technology, today announced, it has been selected by A-Nation as its data and programmatic
‘They Are Scared’ Crypto Ecosystem Pushbacks Over International Monetary Fund Control
Key industry leaders have come up in arms against the International Monetary Fund’s (IMF) statement that cryptocurrencies in general should not be granted legal tender status, saying central banks the world over are losing their grips on world finance.
Why Bath & Body Works Stock Is Sliding After Hours
Bath & Body Works Inc (NYSE: BBWI) shares are trading lower in Wednesday's after-hours session after the company reported strong financial results, but cut earnings guidance below analyst estimates.